This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Silvestri G et al. (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Br Med J 317: 771–775
Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132
Aaronson NK et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
Bergman B et al. (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A: 635–642
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
DM Jackman has received honoraria from both Genentech and Roche, although both fall under the de minimus (<$10,000 per year) as prescribed by Partners Health Systems and Harvard University.
PA Jänne has received an unrestricted grant (>$100,000) from Genentech. He is also part of a pending patent application for epidermal growth factor receptor (EGFR) mutation testing.
Rights and permissions
About this article
Cite this article
Jackman, D., Jänne, P. Does erlotinib improve symptoms in patients with lung cancer?. Nat Rev Clin Oncol 4, 146–147 (2007). https://doi.org/10.1038/ncponc0738
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0738